{"filing":{"accession_number":"0001213900-26-093021","cik":"0000907654","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"ea0302923-8k_oruka.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026093021/ea0302923-8k_oruka.htm"},"events":[{"id":29154,"run_id":26679,"accession_number":"0001213900-26-093021","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Todd Edwards was appointed as Chief Commercial Officer of Oruka Therapeutics, commencing August 24, 2026, pursuant to a letter agreement dated July 22, 2026. The disclosure details his appointment, compensation package (base salary of $525,000, 40% bonus target, stock options and RSUs), and severance arrangements. This is a material executive appointment of a senior officer with significant commercial responsibility at a biopharmaceutical company.","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31333,"accession_number":"0001213900-26-093021","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Todd Edwards was appointed as Chief Commercial Officer of Oruka Therapeutics, commencing August 24, 2026, pursuant to a letter agreement dated July 22, 2026. The disclosure details his appointment, compensation package (base salary of $525,000, 40% bonus target, stock options and RSUs), and severance arrangements. This is a material executive appointment of a senior officer with significant commercial responsibility at a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:08:36.216347+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31333,"accession_number":"0001213900-26-093021","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Todd Edwards was appointed as Chief Commercial Officer of Oruka Therapeutics, commencing August 24, 2026, pursuant to a letter agreement dated July 22, 2026. The disclosure details his appointment, compensation package (base salary of $525,000, 40% bonus target, stock options and RSUs), and severance arrangements. This is a material executive appointment of a senior officer with significant commercial responsibility at a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:08:36.216347+00:00","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-08-24"}]}